The research arm of investment banking firm Goldman Sachswill look to promote Epocrates’ marketing research services. Financial terms ofthe three-year agreement were not disclosed.

Hudson Street, a Goldman Sachs business, will seek toconnect Epocrates to buyside investors and portfolio managers for use ininvestigating potential pharma and biotech investments.

“We have a highly targeted panel that they can reach,” saidKirk Loevner, Epocrates chairman and chief executive officer.

Epocrates claims 500,000 active clinician users in itssubscriber base. Of those, 200,000 are active US physicians, and 145,000 ofthose have opted into the marketing research service.

Epocrates, also known forits clinical information and decision support tools, already works with about150 marketing research firms. They are drawn to the vendor’s ability to tap intoits physician panel, by specialty and by geography, and get answers to surveys.